Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding
NCT02754960Phase 2Withdrawn
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Mar 2010
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in gastrointestinal vascular malformation comparing Thalidomide group with Placebo group (2 arms). Primary endpoint: Proportion of subjects whose bleeding episode decreased from baseline by >= 50% at 12 months. Planned start Mar 2010; status: withdrawn.
02
Drugs
thalidomide
03
Conditions
gastrointestinal vascular malformation
Beyond the preview
Go deeper on NCT02754960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02754960.